India questions legitimacy of WHO anticounterfeiting taskforce
This article was originally published in Scrip
Executive Summary
India has questioned the legitimacy of the World Health Organization-led International Medical Products Anti-Counterfeiting Taskforce (IMPACT), believing it is more of an intellectual property rights (IPRs) and market access initiative, rather than a public health one as it does not "frontally" deal with quality/safety/efficacy (QSE) issues.